TheraRadar
← Back
Data updated: Mar 29, 2026

NOVEN

OncologyMetabolicImmunology
Specialty

NOVEN is a specialty pharmaceutical company focused on Oncology, Metabolic, Immunology. Key products include MINIVELLE.

1996
Since
7
Drugs
-
Trials
15
Approved (2yr)

Key Drugs

MINIVELLE
estradiol
Estrogen Receptor 2 indications · 2012

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

FENTANYL-75 2025-12-22
Labeling
FENTANYL-75 2025-12-22
Labeling
FENTANYL-100 2025-12-22
Labeling
FENTANYL-75 2025-12-22
Labeling
FENTANYL-75 2025-12-22
Labeling
FENTANYL-100 2025-12-22
Labeling
NITROGLYCERIN 2025-12-18
NITROGLYCERIN 2025-04-15
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 43%
0 drugs Phase 3: 13 Phase 2: 14 Phase 1: 43
Metabolic 25%
0 drugs Phase 3: 12 Phase 2: 8 Phase 1: 9
Immunology 11%
0 drugs Phase 3: 5 Phase 2: 5 Phase 1: 2
Cardiovascular 11%
1 drugs Phase 3: 4 Phase 2: 4 Phase 1: 1
Ophthalmology 10%
0 drugs Phase 3: 3 Phase 2: 6 Phase 1: 6

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Novartis big-pharma
Oncology, Cardiovascular, Immunology, Ophthalmology
Merck big-pharma
Oncology, Cardiovascular, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Cardiovascular, Metabolic
Bayer big-pharma
Oncology, Cardiovascular, Ophthalmology, Metabolic
AstraZeneca big-pharma
Oncology, Cardiovascular, Metabolic, Immunology